-

10:54:57 AM

Latest AMGN Stock Market News

AMGN - AMGEN Inc.

06/18/21 5:00 AM

Nasdaq : AMGN

deCODE genetics: Predicting the probability of death

Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.In a paper published today in Communications Biology,

RHEA-AI

neutral

06/15/21 8:00 AM

Nasdaq : AMGN

Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis

Amgen (NASDAQ:AMGN) and Otezla ® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding

RHEA-AI

neutral

06/04/21 5:00 PM

Nasdaq : AMGN

Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive

RHEA-AI

neutral

06/04/21 4:00 PM

Nasdaq : AMGN

Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data

Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRAS TM (sotorasib) in previously treated patients with non-small cell lung cancer (NSCLC)

RHEA-AI

positive

06/04/21 9:00 AM

Nasdaq : AMGN

Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers

Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in

RHEA-AI

neutral

06/01/21 7:00 PM

Nasdaq : AMGN

Amgen to Webcast Investor Meeting at ASCO 2021

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021. David M. Reese, M.D., executive vice president

RHEA-AI

neutral

06/01/21 4:00 AM

Nasdaq, OTC : AMGN, KYKOY

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease AreasKHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory DiseasesModerate-to-Severe Atopic Dermatitis Affects Nearly 30 Million

RHEA-AI

positive

05/28/21 5:00 PM

Nasdaq : AMGN

Amgen To Present At The 2021 Jefferies Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday, June 3, 2021. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present at the conference. Live audio of

RHEA-AI

neutral

05/28/21 12:47 PM

Nasdaq : AMGN

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC),

RHEA-AI

very positive

05/19/21 7:25 PM

Nasdaq : AMGN

Amgen To Present at The Cowen 2nd Annual Virtual Oncology Innovation Summit

Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

AMGN Data

industryBiological Product (except Diagnostic) Manufacturing
websitewww.amgen.com
ceoRobert Bradway
security nameAMGEN Inc.
issue typecs
sectorManufacturing
sic code2836
employees22000
tagsHealth Technology,Biotechnology,Manufacturing,Biological Product (except Diagnostic) Manufacturing
address1 Amgen Center Dr
address2
stateCalifornia
cityThousand Oaks
zip91320-1799
countryUS
phone18054471000

AMGN Description:

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.